Thyme Care completed a $97 million Series D funding led by CVS Health Ventures and prominent investors including Foresite Capital, Morgan Health, and Humana. The company has raised $275 million to date, aiming to scale its value-based care platform that integrates oncology treatment coordination and patient support. This financing reflects increased investor interest in technologies that improve cancer care outcomes while optimizing healthcare utilization and costs.